Background: Patients with mantle cell lymphoma (MCL) follow a heterogeneous clinical course. While they generally require treatment initiation shortly after diagnosis, it is unclear whether deferring treatment in selected patients with an indolent clinical behavior affects their overall outcome.
Introduction
Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL) generally associated with poor outcomes. It is common practice in many institutions to initiate treatment as soon as the diagnosis has been established. Clinical trials of front-line therapy for MCL allow treatment initiation even in the absence of symptoms or other treatment indications that are commonly applied to other indolent NHL [1] [2] [3] . On the other hand, MCL remains incurable even with intensified therapies, and therefore initial treatment deferral may be an acceptable management approach in certain scenarios such as in asymptomatic patients with low disease burden or older or frail patients who may not tolerate standard systemic regimens.
Additionally, MCL has a heterogeneous clinical course, including a proportion of patients with an indolent leukemic non-nodal variant [4] . Several investigators have reported a subgroup of patients with long survival in whom treatment may be deferred without an apparent unfavorable effect on their outcomes [5] [6] [7] [8] [9] [10] [11] . Well-established prognostic factors such as the MCL International Prognostic Index (MIPI) or the proliferative activity as measured by Ki67 immunohistochemistry (IHC) were developed in patients that received immediate treatment, but have not been useful to prospectively identify patients with indolent disease [5] .
Because studies reported so far have been based on a relatively small number of patients, to date it has been difficult to reliably identify patients with indolent MCL at the time of diagnosis. The aim of this study was to describe the subgroup of patients with newly diagnosed MCL who underwent observation as their initial treatment strategy, including their clinical and pathological characteristics, as well as their outcomes.
Patients and methods

Patient identification
All patients diagnosed with MCL between 1998 and 2014 were retrospectively identified using the BCCA Lymphoid Cancer Database, which records information for patients with lymphoid malignancies diagnosed in the Canadian province of BC (population 4.8 million), regardless of place or treatment. Patients are identified through comprehensive and regular review of multiple sources, including medical records and other province-wide cancer registries. The database captures >80% patients with lymphoid malignancies across BC.
Medical records and pathology reports were reviewed to obtain additional information. Pathology was centrally reviewed at the time of diagnosis, and only cases positive for cyclin D1 by IHC and/or translocation (11;14) by fluorescence in situ hybridization were included. Patients too frail for treatment at initial diagnosis were excluded. Throughout the study period, bone marrow biopsies and contrast-enhanced computed tomography scans of the chest, abdomen, and pelvis were routinely carried out to determine Ann Arbor stage. Gastrointestinal endoscopies and positron-emission tomography scans were not routinely carried out.
Observation was defined as treatment deferral for !3 months from the date of definitive diagnosis, consistent with a prior study of observation in MCL [5] . This cut-off was judged as the minimum length of time for observation to be considered as a clinically relevant first-line management strategy. There were no predefined criteria guiding observation or active treatment. In general, treatment indications included high tumor burden, disease associated symptoms, or peripheral blood cytopenias. The date of eventual chemotherapy initiation was verified for all patients who were initially observed using the BCCA Provincial Pharmacy Database.
Clinical and biological features at diagnosis, including disease distribution (nodal versus non-nodal versus gastrointestinal), MIPI scores, treatment received, and follow-up data were analyzed. Bulky disease was defined as the largest nodal mass measuring !10 cm. The 'nodal' group was defined as patients presenting predominantly with lymphadenopathy, with or without extranodal sites such as the bone marrow or gastrointestinal tract. The 'non-nodal' group was defined as patients presenting with lymphocytosis and/or splenomegaly but without significant lymphadenopathy. The 'gastrointestinal' group was defined as patients with exclusive gastrointestinal tract involvement.
Pathologic and molecular data
All pathology reports were reviewed to confirm the diagnosis of MCL and to obtain the histological variant (blastoid versus non-blastoid), proliferation index (Ki67 by IHC), TP53 status by IHC (positive versus negative), and SOX11 by IHC (positive versus negative). In patients with an available lymph node biopsy and >60% tumor content, the formalinfixed, paraffin-embedded tissue was analyzed using a gene expressionbased assay measuring the MCL proliferative signature [12] , a biomarker first described by Rosenwald et al. [13] . This assay, the MCL35, has been validated for use in lymph node biopsies with a tumor content of 60% or greater and was only applied to biopsies that fulfilled that criterion. Briefly, Ki67 (MIB-1), TP53, and SOX11 IHC were carried out on tissue microarrays using duplicate 0.6 mm cores. All stains were scored independently by two hematopathologists (GS, AM). Ki67 was visually scored in 10% increments and then grouped into previously described categories: <30% and !30% [14] . Positivity for TP53 was defined as strong uniform nuclear staining, while SOX11 was considered positive if any tumor cells stained. In patients with missing IHC or MCL35 data, archival tissue was not retrieved to complete this testing.
Statistical methods
Patient and disease characteristics were compared between observation and early treatment groups. The t-test was used to compare continuous variables, and the chi-squared test was used to compare categorical variables. Time to treatment (TtT) was defined as the time from definitive diagnosis of MCL to treatment initiation (chemotherapy or radiation therapy).
Overall survival (OS) was defined as the time from initial diagnosis to death from any cause. Actuarial survival curves were estimated using the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazards regression analysis was used to compare the early treatment and observation groups after adjustment for other prognostic factors. Patients in the observation group were by definition expected to have more favorable outcomes as they survived !3 months. In order to account for this bias and allow a fair comparison to those treated <3 months, patients who died within 3 months after diagnosis in the early treatment group (n ¼ 10) were excluded from the analyses comparing OS between these two groups.
P < 0.05 was considered significant. All statistical analyses were carried out using the SPSS 17.0 software program for Windows (SPSS Inc., Chicago, IL). The study was approved by the University of British Columbia/BCCA Research Ethics Board.
Results
Patient characteristics
A total of 725 patients diagnosed with MCL between 1998 and 2014 were initially identified, but 285 were excluded: unavailable treatment and/or follow-up data (n ¼ 179), absence of cyclin D1 or t(11;14) confirmation (n ¼ 83), no treatment due to frailty (n ¼ 16), and treatment refusal (n ¼ 7). In the present analysis, 365 (83%) patients received treatment within 3 months after MCL diagnosis and were defined as the early treatment group, while 75 (17%) were observed for !3 months after diagnosis and were defined as the observation group. Table 1 shows that patients in the observation group had more favorable features including better performance status, less frequent B symptoms or increased LDH levels, non-bulky disease, no blastoid morphology, and lower Ki67 values in comparison to the early treatment group. Non-nodal and gastrointestinal presentations occurred more frequently in observed patients. Characteristics not associated with the decision for deferred treatment included age at diagnosis, sex, leukocyte count, platelet count, stage, TP53, SOX11, and MIPI. The majority of patients received rituximab-containing chemotherapy at the time of initial treatment. Figure 1A shows that in the observation cohort, with a median follow-up of 48 months (range 3.4-158) in living patients, the median TtT was 35 months (range 5-79). Sixty patients (80%) were observed for at least 12 months without requiring treatment, including 10 patients (13%) who did not require treatment for at least 5 years. Ultimately, 29 patients did not receive treatment, although 5 experienced eventual MCL progression (age range 80-92) but were too frail for any treatment. The median followup in the 24 patients without MCL progression and who did not require treatment was 35 months (range 3.4-158). Table 2 and Figure 1B show that clinical presentation was the only variable significantly associated with TtT: nodal (median TtT 25 months) versus non-nodal (median TtT not reached) versus gastrointestinal (median TtT 59 months) (P ¼ 0.012). All other factors, including MIPI and both markers of proliferation, the Ki67 and the MCL35 assay, were not predictive for TtT in the observed patients.
TtT in observed patients
Survival outcomes
In the entire cohort, the median follow-up in living patients was 46 months (range 0.5-158), with no difference between the observation and early treatment groups (P ¼ 0.574). The median OS was significantly longer in the observation group than in the early treatment group (72 versus 52.5 months, respectively, P ¼ 0.041), as shown in Figure 1C . The median OS after first-line therapy in observed patients (n ¼ 46) was 34 months (range 0.4-113.5). In the observation group, age at diagnosis, stage, LDH, and histological pattern did not impact OS, while clinical presentation (nodal, non-nodal, or gastrointestinal) (median OS 47 months versus 124 months versus not reached, respectively, P ¼ 0.009, Figure 1D ) and TP53 status by IHC ( Figure 1E ) were the only factors associated with OS. In contrast to the early treatment group, proliferation was not prognostic in the observed patients, although the number of patients in the high-risk groups for Ki67 and MCL35 assay was very small (7 and 1, respectively).
The impact of treatment initiation on OS (observation versus early treatment) was analyzed in a multivariate Cox proportional hazards regression model together with other prognostic factors including MIPI risk categories (low versus intermediate versus high), stage (I/II versus III/IV), clinical presentation (nodal versus non-nodal) and blastoid morphology (blastoid versus non-blastoid) (supplementary Table S1 , available at Annals of Oncology online). Ki67, TP53, SOX11, and MCL35 were not included in the multivariate models to maintain statistical power and reduce bias, as these were largely carried out in a subset of patients with available nodal tissue. In this model, treatment group (observation versus early treatment) was not associated with OS [HR 0.804 (95% CI 0.529-1.221), P ¼ 0.306], while the other prognostic factors retained their independent prognostic association.
Discussion
In this large population-based cohort of patients with MCL managed over almost two decades, 17% were observed beyond 3 months after diagnosis. With a median follow-up of 4 years, about 1 in 5 observed patients did not require initiation of firstline therapy. Among the various clinical and pathologic factors analyzed, a non-nodal presentation was the single factor most strongly associated with prolonged TtT and excellent OS. Ultimately, treatment deferral did not impact OS, and avoided unnecessary treatment in 24/440 (5%) patients.
Our data suggest that disease biology was the driving factor behind physicians' decision to treat or observe. Patients in the early treatment group had worse performance status, more B symptoms, lower median hemoglobin levels, more frequent LDH elevation, larger nodal masses, more frequent nodal disease distribution, more frequent blastoid morphology, and higher Ki67 scores. Median OS was significantly longer in the 0 1 2 3 4 5 6 7 8 9 10 11 12 13 0 1 2 3 4 5 6 7 8 9 10 11 12 13 observation group than in the early treatment group, probably reflecting their more favorable disease characteristics. Furthermore, the association between observation and OS did not achieve statistical significance in a multivariate Cox proportional hazards regression model that included other prognostic indicators. The lack of a detrimental effect of observation on OS argues that treatment deferral remains a valid initial management strategy for selected patients with MCL. Our findings are consistent with other smaller, retrospective studies showing that deferring initial treatment does not adversely impact the outcomes of a subgroup of patients with MCL [5] [6] [7] [8] [9] . The largest published study is a retrospective cohort of 97 patients with MCL in which approximately one-third were observed for >3 months since diagnosis. In this subgroup of patients, the median time from diagnosis to treatment initiation was 12 months (range 4-128) with no adverse impact on outcomes. Most of these patients had typical MCL presenting with non-bulky, slowly progressive nodal disease [5] . The proportion of patients considered suitable for observation was lower in the present study in comparison to that particular series (17% versus 32%, respectively). This discrepancy may reflect differences in how patients were selected for observation in a population versus an academic center series, differences in sample size, or a bias to treat younger patients given favorable outcomes observed with autologous stem cell transplantation [15] . Presently, data on observation as an initial management strategy in MCL remain limited, particularly in terms of predictive factors that can reliably identify those patients unlikely to be compromised by a watchful waiting approach. In our cohort, the MIPI showed a similar risk distribution between both groups, which could be explained in part because of the use of WBC as a continuous variable in the MIPI together with a higher frequency of non-nodal cases in the observation group. In this sense, the MIPI also failed to predict OS in this group in contrast with the early treatment group. Similarly, proliferation was not predictive for TtT or OS in the observation group while it remained strongly predictive for OS in the early treatment group. Ki67 scores were mostly low in the observation group, and only 14% of patients presented with Ki67 !30%, which may account for the lack of predictive power of Ki67. In addition, Ki67 was not analyzed in the non-nodal cases primarily due to lack of sufficient tissue biopsy in these cases.
Clinical presentation, particularly in patients with non-nodal distribution has, as previously reported, a favorable outcome in terms of TtT and OS, and corresponds to a subgroup of patients who may be safely observed [16] [17] [18] [19] [20] [21] . Many of these cases may actually have leukemic non-nodal MCL, which has distinct biological characteristics such as hypermutated immunoglobulin genes, noncomplex karyotypes and a different gene expression profile in comparison with typical MCL [7, 22, 23] . In our study, all of the 27 non-nodal cases presented with a peripheral blood lymphocytosis [median lymphocyte count 11.7Â 10 9 /l (range 4.2-61) in 16 observed patients, and 23Â 10 9 /l (range 7.3-528) in 11 patients treated early], suggesting the majority likely had leukemic non-nodal MCL. However, we cannot determine the exact number of cases with leukemic non-nodal MCL as other defining parameters are incomplete (SOX11, Ki67) or unavailable (IGVH status, gene expression profiling). Because IHC data were almost completely unavailable in cases with peripheral blood, bone marrow, and GI involvement, our data underestimate the role of Ki67, TP53, and SOX11 in the non-nodal cases, which in turn, are the most likely to have an indolent clinical behavior.
Despite our retrospective design with considerable selection bias as to how patients were deemed suitable for observation, management has been relatively uniform throughout 17 years in terms of choosing observation versus early treatment (Table 1) . Even though certain baseline investigations, particularly IHC for Ki67, TP53, and SOX11, were not routinely carried out largely due to limited diagnostic material, this is the largest cohort reported analyzing the impact of observation in MCL. Notwithstanding these limitations, our study suggests that a subgroup of patients with MCL may be safely observed at diagnosis of the disease without negatively impacting their outcomes, including not only those patients with a non-nodal distribution, but also asymptomatic patients with low-burden nodal presentation and a low Ki67 score. These data could give rise to a future randomized trial investigating the outcome with deferred versus immediate treatment in a prospectively defined group of indolent MCL patients.
